Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas
eLife · 2024
DOI: 10.7554/elife.96257 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Danielle Algranati und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel. Hauptthemen laut MEDLINE: Glioma, Histone Deacetylases, Histones, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, The Israel Science Foundation, Emerson Collective.
Abstract (Originalsprache)
Diffuse midline gliomas (DMGs) are aggressive and fatal pediatric tumors of the central nervous system that are highly resistant to treatments. Lysine to methionine substitution of residue 27 on histone H3 (H3-K27M) is a driver mutation in DMGs, reshaping the epigenetic landscape of these cells to promote tumorigenesis. H3-K27M gliomas are characterized by deregulation of histone acetylation and methylation pathways, as well as the oncogenic MYC pathway. In search of effective treatment, we examined the therapeutic potential of dual targeting of histone deacetylases (HDACs) and MYC in these tumors. Treatment of H3-K27M patient-derived cells with Sulfopin, an inhibitor shown to block MYC-driven tumors in vivo, in combination with the HDAC inhibitor Vorinostat, resulted in substantial decrease in cell viability. Moreover, transcriptome and epigenome profiling revealed synergistic effect of this drug combination in downregulation of prominent oncogenic pathways such as mTOR. Finally, in vivo studies of patient-derived orthotopic xenograft models showed significant tumor growth reduction in mice treated with the drug combination. These results highlight the combined treatment with PIN1 and HDAC inhibitors as a promising therapeutic approach for these aggressive tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.
- Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel.
- Bioinformatics Unit, Department of Life Sciences Core Facilities, Faculty of Biochemistry, Weizmann Institute of Science, Rehovot, Israel.
- Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel.
- Department of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
- Racah Institute of Physics, Hebrew University, Jerusalem, Israel.
ORCID-Profile: Roni Oren, Guy Ron, Noa Furth, Efrat Shema
Förderung
- European Research Council
- The Israel Science Foundation
- Emerson Collective
- The Israeli Cancer Research Fund
Zitieren
APA
Algranati, D., Oren, R., Dassa, B., Fellus-Alyagor, L., Plotnikov, A., Barr, H., Harmelin, A., London, N., Ron, G., Furth, N., & Shema, E. (2024). Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas. eLife. https://doi.org/10.7554/elife.96257
Vancouver
Algranati D, Oren R, Dassa B, Fellus-Alyagor L, Plotnikov A, Barr H, et al. Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas. eLife. 2024. doi:10.7554/elife.96257
BibTeX
@article{Algranati2024,
author = {Algranati, Danielle and Oren, Roni and Dassa, Bareket and Fellus-Alyagor, Liat and Plotnikov, Alexander and Barr, Haim and Harmelin, Alon and London, Nir and Ron, Guy and Furth, Noa and Shema, Efrat},
title = {Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.96257}
}
EUVIMED